13 Jun 2022 07:00
13 June 2022
DeepVerge PLC
("DeepVerge" or "the Company")
Notice of Final Results and Annual Report
Skin Trust Club continues to expand with accelerated momentum
DeepVerge (LSE:DVRG.L) today announces that it will publish its Final Results and Annual Report for the year ended 31 December 2021 on 23 June 2022.
Gerard Brandon, CEO of DeepVerge, comments:
"As we prepare to publish our Annual Report demonstrating growth across the whole business, Skin Trust Club has rapidly become a key segment of the Labskin Division. We continue to see accelerated growth with the number of repeat customers; countries in which we are now operating; additional skincare brands on our marketplace app plus numerous high-profile companies from different industry sectors wanting to work with us. In a $145 billion skincare market, Skin Trust Club is the new era of personalised skin care."
Skin Trust Club:
Having recently been awarded the Best New Disruptor Brand 2022 from the Pure Beauty Global Awards, and concluding a study showing more than 63% of people get their skin type wrong, Skin Trust Club is helping thousands of members get it right.
Skin Trust Club has the largest skin microbiome database in the world and the range of applications is expanding:
▪ Skin Trust Club B2C: Member home test kit.
▪ Skin Trust Club B2B: Test kit sales and data intelligence to our retail partners through an affiliate programme.
▪ Skin Trust Club B2B: Affiliate programme sales.
▪ Skin Trust Medical B2B: Home test kit referral services for dermatology professionals in development.
● Skin Trust Club has over 20,000 members with more than 50,000 visits per month.
● The marketplace service is expanding rapidly with more than 300 products now available.
● Intense interest from the US market resulted in unprecedented demand for Skin Trust Club test kits.
For further information please contact:
DeepVerge plc | Gerard Brandon, CEO | +44 (0) 7340 055 648 |
SPARK Advisory Partners Limited (Nominated Adviser) | Neil Baldwin/Andrew Emmott | +44 (0) 113 370 8974 |
Turner Pope Investments (TPI) Limited (Broker) | Andy Thacker/James Pope | +44 (0) 20 3657 0050 |
About DeepVerge plc (www.deepverge.com)
DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.
Skin Trust Club
Skin Trust Club incorporates an artificial intelligence Skincare App and Home Test Kit that provide simple, at-home skin microbiome testing for personalised skincare and skin health tracking. The self-administered skin swab is a remote trial and allows the participant to conduct each stage of the trial without interaction. Skin Trust Club's DNA Test generates a report that consumers can use to manage their custom skincare regime. Analysis of skin attributes provides information to create hundreds of different product combinations to suit a person's unique skin microbiome.
Labskin (Life Science Division)
Labskin is a 3D human skin equivalent test platform that scientifically proves the impact of skincare product claims in healthcare, life sciences, skin microbiome clinical trials, pharmaceutical and cosmetics industries. Labskin have been pioneering the development of a laboratory grown human skin platform for 15 years and is the only commercially available lab-grown full thickness human skin model that naturally mimics the skins' microbiome. Labskin's virtual clinical trials with remote collection of human volunteers' skin microbiome provides a solution for the collection of volunteer microbiomes to allow for lab-controlled trials of advanced skin models and human microbiomes. As the data bank of remote volunteers grows, the higher the accuracy and increased reliability of virtual product testing that can be provided to clients, eliminating early human trial and error testing and resulting in a faster time to market. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing products, that shows the positive or negative impact on skin's natural microflora.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.